Wiley and OpenEvidence Partner to Deliver Trusted Research to Physicians at the Point of Care
A new content agreement deepens the medical literature physicians can retrieve, synthesize, and verify through AI-assisted clinical questions
Wiley (NYSE:WLY), a global leader in authoritative content and research intelligence for the advancement of clinical practice, scientific discovery and learning, and OpenEvidence, the most widely used medical AI platform in the world, today announced a strategic partnership to bring Wiley's trusted scientific and medical content into OpenEvidence. Through the partnership, physicians using OpenEvidence at the point of care can rely on content from hundreds of Wiley's peer-reviewed journals and resources across key medical specialties to support their clinical decisions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303408088/en/
Medical knowledge doubles every 73 days. Historically, published research has taken an average of 17 years to reach clinical practice. Helping doctors make point-of-care decisions grounded in the best and latest science requires more than capable AI; it needs the right underlying content. OpenEvidence was built on a principle its founders call "gold in, gold out": specialized models trained on peer-reviewed literature, not the open internet, with every answer grounded in sources a physician can drill into and verify. By joining OpenEvidence's existing network of content partners, Wiley extends that foundation.
"The hard problem in medicine right now isn't just generating new knowledge. We are living through a golden age of biomedical research. The hard problem is also that it takes 17 years for a fraction of that research to reach the bedside," said Daniel Nadler, founder of OpenEvidence. "Wiley is an ideal partner in solving this problem for physicians. The depth and breadth of Wiley's content reinforce the advantages of OpenEvidence for physicians, and that compounds over time."
Wiley will license a comprehensive portfolio of scientific and medical content to OpenEvidence, including the Cochrane Database of Systematic Reviews—the home of gold standard evidence syntheses, widely used to inform clinical guidelines worldwide—and Cochrane Clinical Answers—a curated collection of actionable clinical insights drawn from Cochrane reviews.
"Cochrane systematic reviews are relied upon by evidence users worldwide, from patients and healthcare professionals to guideline-setters and policymakers," said Karla Soares-Weiser, CEO of Cochrane. "AI is rapidly changing the ways that people use and access evidence, and we hope that this partnership helps to ensure that outputs from AI-powered tools are based on the best possible evidence."
Additionally, the portfolio will comprise over 400 Wiley journals and books, including authoritative medical references such as Holland-Frei Cancer Medicine, Rook's Dermatology Handbook, and Yamada's Textbook of Gastroenterology. The content, which spans medical specialties including cardiology, endocrinology, geriatrics, hematology, internal medicine, neurology, obstetrics, oncology, psychiatry, and rheumatology, will be referenced inside OpenEvidence's evidence layer, cited with the same transparency that has earned the platform the trust of more than 40% of U.S. physicians.
For clinicians, the practical effect is broader and deeper access to trustworthy evidence at the point of care. The question a physician encounters once in a career is often the one where the evidence is most essential and where a dead-end search carries the highest cost. Wiley's corpus deepens the literature available in OpenEvidence for precisely those queries, expanding the range of clinical questions that return a source-cited, evidence-based answer without leaving the point-of-care workflow.
"At the end of the day, we believe doctors will be able to make better decisions because we're bringing Wiley's vast portfolio of peer-reviewed scientific and medical content into OpenEvidence, where those decisions are getting made," said Matt Kissner, president and CEO of Wiley. "We're excited about this partnership, which reflects our broader commitment to integrating trusted scientific knowledge into the technologies driving innovation across healthcare and life sciences."
The partnership positions Wiley and OpenEvidence to explore future collaboration opportunities together, including deepening society relationships, connections across networks, global expansion, and other healthcare and life sciences use cases.
"The gap between published research and clinical practice has persisted for decades. Every content partnership that puts peer-reviewed evidence directly into the physician's workflow makes that gap narrower. This one makes it meaningfully so," added Daniel Nadler.
About Wiley
Wiley (NYSE:WLY) is a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning. With more than 200 years at the center of the scholarly ecosystem, Wiley combines trusted publishing heritage with AI-powered platforms to transform how knowledge is discovered, accessed, and applied. From individual researchers and students to Fortune 500 R&D teams, Wiley enables the transformation of scientific breakthroughs into real-world impact. From knowledge to impact: Wiley is redefining what's possible in science and learning. Visit us at Wiley.com and Investors.Wiley.com. Follow us on Facebook, X, LinkedIn and Instagram.
About OpenEvidence
OpenEvidence is the most widely used medical AI platform among U.S. physicians, and is trusted by hundreds of thousands of verified clinicians to make high-stakes clinical decisions at the point of care with answers that are sourced, cited, and grounded in peer-reviewed medical literature. OpenEvidence was founded with the mission to organize and expand the world's collective medical knowledge. Learn more at openevidence.com.
Category: All Corporate News
Category: All Journals and Research
View source version on businesswire.com: https://www.businesswire.com/news/home/20260303408088/en/
OpenEvidence
[email protected]
Wiley
[email protected]